Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study
We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV...
Saved in:
Published in | Open forum infectious diseases Vol. 5; no. 3; p. ofy040 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.03.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treatment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan.
We developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost.
Increasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very cost-effective in Georgia (ICER = $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interventions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it became cost-effective/cost-saving in all countries when we decreased DAA costs.
Increasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new infections if associated with NSP+OST. |
---|---|
AbstractList | BACKGROUNDWe evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treatment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan. METHODSWe developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost. RESULTSIncreasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very cost-effective in Georgia (ICER = $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interventions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it became cost-effective/cost-saving in all countries when we decreased DAA costs. CONCLUSIONIncreasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new infections if associated with NSP+OST. Abstract Background We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treatment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan. Methods We developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost. Results Increasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very cost-effective in Georgia (ICER = $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interventions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it became cost-effective/cost-saving in all countries when we decreased DAA costs. Conclusion Increasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new infections if associated with NSP+OST. We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treatment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan. We developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost. Increasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very cost-effective in Georgia (ICER = $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interventions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it became cost-effective/cost-saving in all countries when we decreased DAA costs. Increasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new infections if associated with NSP+OST. |
Author | Konorazov, Ivan Popovici, Svetlana Scutelniciuc, Otilia Malkin, Jean-Elie Mabileau, Guillaume Saifuddin, Karimov Manova, Manoela Saldanha, Vinay Yazdanpanah, Yazdan Yelizaryeva, Alla Tsereteli, Maia Losina, Elena |
AuthorAffiliation | 8 National AIDS Control center, Ministry of Health and Social Protection, Dushanbe, Tajikistan 1 INSERM, IAME, UMR, Paris, France 3 UNAIDS Country office, Almaty, Kazakhstan 7 Hospital of Dermatology and Communicable Diseases, Chisinau, Republic of Moldova 12 AP-HP, Bichat-Claude Bernard Hospital, Infectious Diseases Department, Paris, France 5 Ministry of Health of Belarus, Minsk, Belarus 11 Global Alliance for Health and Social Compact, Taunton, United Kingdom 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France 4 Department of HIV/AIDS, Hepatitis, STI and TB, National Center for Disease Control and Public Health, Tbilisi, Georgia 6 Republican Center for AIDS Prevention and Control, Almaty, Kazakhstan 9 Harvard Medical School, Boston, Massachusetts 10 UNAIDS Regional Office for Europe and Central Asia, Moscow, Russia |
AuthorAffiliation_xml | – name: 9 Harvard Medical School, Boston, Massachusetts – name: 11 Global Alliance for Health and Social Compact, Taunton, United Kingdom – name: 7 Hospital of Dermatology and Communicable Diseases, Chisinau, Republic of Moldova – name: 5 Ministry of Health of Belarus, Minsk, Belarus – name: 1 INSERM, IAME, UMR, Paris, France – name: 8 National AIDS Control center, Ministry of Health and Social Protection, Dushanbe, Tajikistan – name: 3 UNAIDS Country office, Almaty, Kazakhstan – name: 10 UNAIDS Regional Office for Europe and Central Asia, Moscow, Russia – name: 12 AP-HP, Bichat-Claude Bernard Hospital, Infectious Diseases Department, Paris, France – name: 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France – name: 4 Department of HIV/AIDS, Hepatitis, STI and TB, National Center for Disease Control and Public Health, Tbilisi, Georgia – name: 6 Republican Center for AIDS Prevention and Control, Almaty, Kazakhstan |
Author_xml | – sequence: 1 givenname: Guillaume surname: Mabileau fullname: Mabileau, Guillaume organization: Université Paris Diderot, Sorbonne Paris Cité, Paris, France – sequence: 2 givenname: Otilia surname: Scutelniciuc fullname: Scutelniciuc, Otilia organization: UNAIDS Country office, Almaty, Kazakhstan – sequence: 3 givenname: Maia surname: Tsereteli fullname: Tsereteli, Maia organization: Department of HIV/AIDS, Hepatitis, STI and TB, National Center for Disease Control and Public Health, Tbilisi, Georgia – sequence: 4 givenname: Ivan surname: Konorazov fullname: Konorazov, Ivan organization: Ministry of Health of Belarus, Minsk, Belarus – sequence: 5 givenname: Alla surname: Yelizaryeva fullname: Yelizaryeva, Alla organization: Republican Center for AIDS Prevention and Control, Almaty, Kazakhstan – sequence: 6 givenname: Svetlana surname: Popovici fullname: Popovici, Svetlana organization: Hospital of Dermatology and Communicable Diseases, Chisinau, Republic of Moldova – sequence: 7 givenname: Karimov surname: Saifuddin fullname: Saifuddin, Karimov organization: National AIDS Control center, Ministry of Health and Social Protection, Dushanbe, Tajikistan – sequence: 8 givenname: Elena surname: Losina fullname: Losina, Elena organization: Harvard Medical School, Boston, Massachusetts – sequence: 9 givenname: Manoela surname: Manova fullname: Manova, Manoela organization: UNAIDS Regional Office for Europe and Central Asia, Moscow, Russia – sequence: 10 givenname: Vinay surname: Saldanha fullname: Saldanha, Vinay organization: UNAIDS Regional Office for Europe and Central Asia, Moscow, Russia – sequence: 11 givenname: Jean-Elie surname: Malkin fullname: Malkin, Jean-Elie organization: Global Alliance for Health and Social Compact, Taunton, United Kingdom – sequence: 12 givenname: Yazdan surname: Yazdanpanah fullname: Yazdanpanah, Yazdan organization: AP-HP, Bichat-Claude Bernard Hospital, Infectious Diseases Department, Paris, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29594179$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1q3DAUhUVJadI0q-7LXRaKU8myR1YXhWGaZgwJDf1Jl0KWr2ec2pIj2YF5qTxjNDNJSLXQFZyj71w4b8mBdRYJec_oKaOSf3ZNW8drQzP6ihylPC2SQubi4MX7kJyEcEMpZYzmVMg35DCVucyYkEfkvrQj-ju0Y-ssXGnzT68wwOjgJ9aTQRjXCGU_aDOCa2BZXoO2NSwX11DaBs32W4B57-wKrtANHcLftYvaTdTgm59WAVoLZzrEmDgn7wbcIRYx0-sO5qHVX2AOl67Gro2YnejCmGCzC4jLYQjwa5zqzTvyutFdwJPHeUz-fD_7vVgmFz_Oy8X8IjG8YGPCTCorzWeVoDmmosqzhjbprNKIPM-M5vGwCoXQBcvTIkVe15pKzCqqI6Dhx-TrnjtMVY-12e-qBt_22m-U0636X7HtWq3cncqLGcuoiICPjwDvbicMo-rbYLDrtEU3BZVSJgtaSJFH66e91XgXgsfmOYZRtS1ZbUtW-5Kj-8PLzZ69T5XyB6TzqBg |
CitedBy_id | crossref_primary_10_1097_COH_0000000000000571 crossref_primary_10_1111_add_15630 crossref_primary_10_1016_j_jhepr_2019_06_006 crossref_primary_10_3389_fgene_2023_1171892 crossref_primary_10_1016_S2214_109X_20_30003_6 crossref_primary_10_1016_S2468_1253_19_30085_8 crossref_primary_10_1093_epirev_mxab013 crossref_primary_10_1016_S2352_3018_21_00274_5 crossref_primary_10_1093_ofid_ofab457 crossref_primary_10_4254_wjh_v10_i10_639 crossref_primary_10_1002_jia2_26208 crossref_primary_10_1002_jia2_25139 crossref_primary_10_1111_apt_15201 |
Cites_doi | 10.1097/01.olq.0000221335.80508.fa 10.1097/QAD.0000000000000298 10.1093/cid/ciw416 10.1371/journal.pmed.1000423 10.1111/j.1360-0443.2004.00899.x 10.1016/j.drugpo.2014.01.007 10.1097/QAD.0000000000000307 10.1503/cmaj.080808 10.1016/S0277-9536(96)00258-4 10.1186/1477-7517-2-16 10.1371/journal.pone.0045176 10.1111/j.1360-0443.2011.03515.x 10.1097/QAD.0b013e328010c7d0 |
ContentType | Journal Article |
Copyright | The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2018 |
Copyright_xml | – notice: The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2018 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1093/ofid/ofy040 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2328-8957 |
EndPage | ofy040 |
ExternalDocumentID | 10_1093_ofid_ofy040 29594179 |
Genre | Journal Article |
GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E NPM O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c381t-1c29ba36b705e27b54f0f26baee354ca33331be77a815282e3dda09e4b0a381f3 |
IEDL.DBID | RPM |
ISSN | 2328-8957 |
IngestDate | Tue Sep 17 21:22:03 EDT 2024 Sat Aug 17 03:57:47 EDT 2024 Fri Aug 23 02:37:27 EDT 2024 Tue Aug 27 13:53:16 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | cost-effectiveness Eastern Europe & Central Asia HIV hepatitis C people who inject drugs |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c381t-1c29ba36b705e27b54f0f26baee354ca33331be77a815282e3dda09e4b0a381f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861407/ |
PMID | 29594179 |
PQID | 2019808975 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5861407 proquest_miscellaneous_2019808975 crossref_primary_10_1093_ofid_ofy040 pubmed_primary_29594179 |
PublicationCentury | 2000 |
PublicationDate | 2018-03-01 |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: US |
PublicationTitle | Open forum infectious diseases |
PublicationTitleAlternate | Open Forum Infect Dis |
PublicationYear | 2018 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Turner (2020081004173003600_CIT0015) 2011; 106 Pinkerton (2020081004173003600_CIT0020) 1997; 44 UNAIDS (2020081004173003600_CIT0001) 2014 Cipriano (2020081004173003600_CIT0007) 2012; 7 Global Commission on Drug Policy (2020081004173003600_CIT0003) 2013 Bouscaillou (2020081004173003600_CIT0004) 2014; 25 Lasry (2020081004173003600_CIT0018) 2014; 28 Dutta (2020081004173003600_CIT0008) 2013 UNAIDS (2020081004173003600_CIT0022) 2014 Low (2020081004173003600_CIT0024) 2016; 63 Alistar (2020081004173003600_CIT0009) 2011; 8 Patel (2020081004173003600_CIT0017) 2014; 28 World Health Organization (2020081004173003600_CIT0023) 2015 2020081004173003600_CIT0016 Long (2020081004173003600_CIT0012) 2006; 20 World Health Organization (2020081004173003600_CIT0014) 2003 Wilson (2020081004173003600_CIT0013) 2012 Barcal (2020081004173003600_CIT0021) 2005; 2 Terrault (2020081004173003600_CIT0019) 2002; 36 Vickerman (2020081004173003600_CIT0010) 2006; 33 Bayoumi (2020081004173003600_CIT0006) 2008; 179 Eurasian Harm Reduction Network (EHRN) (2020081004173003600_CIT0005) 2012 Kumaranayake (2020081004173003600_CIT0011) 2004; 99 Rapid Response Service (2020081004173003600_CIT0025) 2014 UNAIDS (2020081004173003600_CIT0002) |
References_xml | – volume-title: The Global HIV Epidemics Among People Who Inject Drugs year: 2013 ident: 2020081004173003600_CIT0008 contributor: fullname: Dutta – volume: 33 start-page: S89 year: 2006 ident: 2020081004173003600_CIT0010 article-title: The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine publication-title: Sex Transm Dis doi: 10.1097/01.olq.0000221335.80508.fa contributor: fullname: Vickerman – volume: 28 start-page: 1509 year: 2014 ident: 2020081004173003600_CIT0017 article-title: Estimating per-act HIV transmission risk: a systematic review publication-title: AIDS doi: 10.1097/QAD.0000000000000298 contributor: fullname: Patel – volume: 63 start-page: 1094 year: 2016 ident: 2020081004173003600_CIT0024 article-title: Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis publication-title: Clin Infect Dis doi: 10.1093/cid/ciw416 contributor: fullname: Low – volume: 8 start-page: e1000423 year: 2011 ident: 2020081004173003600_CIT0009 article-title: Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine publication-title: PLoS Med doi: 10.1371/journal.pmed.1000423 contributor: fullname: Alistar – volume: 99 start-page: 1565 year: 2004 ident: 2020081004173003600_CIT0011 article-title: The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus publication-title: Addiction doi: 10.1111/j.1360-0443.2004.00899.x contributor: fullname: Kumaranayake – volume-title: Hepatitis C Virus (HCV) Re-infection Rates Among People Who Use Drug year: 2014 ident: 2020081004173003600_CIT0025 contributor: fullname: Rapid Response Service – year: 2012 ident: 2020081004173003600_CIT0005 contributor: fullname: Eurasian Harm Reduction Network (EHRN) – ident: 2020081004173003600_CIT0002 contributor: fullname: UNAIDS – start-page: 78 year: 2015 ident: 2020081004173003600_CIT0023 contributor: fullname: World Health Organization – volume: 25 start-page: 871 year: 2014 ident: 2020081004173003600_CIT0004 article-title: Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2014.01.007 contributor: fullname: Bouscaillou – ident: 2020081004173003600_CIT0016 – volume: 28 start-page: 1521 year: 2014 ident: 2020081004173003600_CIT0018 article-title: HIV sexual transmission risk among serodiscordant couples: assessing the effects of combining prevention strategies publication-title: AIDS doi: 10.1097/QAD.0000000000000307 contributor: fullname: Lasry – volume: 179 start-page: 1143 year: 2008 ident: 2020081004173003600_CIT0006 article-title: The cost-effectiveness of Vancouver’s supervised injection facility publication-title: CMAJ doi: 10.1503/cmaj.080808 contributor: fullname: Bayoumi – volume-title: The negative impact of the war on drugs on public health: The hidden hepatitis C epidemic year: 2013 ident: 2020081004173003600_CIT0003 contributor: fullname: Global Commission on Drug Policy – volume: 44 start-page: 1303 year: 1997 ident: 2020081004173003600_CIT0020 article-title: Effectiveness of condoms in preventing HIV transmission publication-title: Soc Sci Med doi: 10.1016/S0277-9536(96)00258-4 contributor: fullname: Pinkerton – volume: 2 start-page: 16 year: 2005 ident: 2020081004173003600_CIT0021 article-title: A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine publication-title: Harm Reduct J doi: 10.1186/1477-7517-2-16 contributor: fullname: Barcal – volume: 7 start-page: e45176 year: 2012 ident: 2020081004173003600_CIT0007 article-title: Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users publication-title: PLoS One doi: 10.1371/journal.pone.0045176 contributor: fullname: Cipriano – volume: 106 start-page: 1978 year: 2011 ident: 2020081004173003600_CIT0015 article-title: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence publication-title: Addiction doi: 10.1111/j.1360-0443.2011.03515.x contributor: fullname: Turner – volume-title: Making choices in health: WHO guide to cost-effectiveness analysis year: 2003 ident: 2020081004173003600_CIT0014 contributor: fullname: World Health Organization – volume-title: 90-90-90 - An ambitious treatment target to help end the AIDS epidemic year: 2014 ident: 2020081004173003600_CIT0022 contributor: fullname: UNAIDS – year: 2012 ident: 2020081004173003600_CIT0013 article-title: Needle-syringe programs are cost-effective in Eastern Europe and Central Asia: costing, data synthesis, modeling and economics for eight case study countries publication-title: UNAIDS contributor: fullname: Wilson – volume: 36 start-page: S99 year: 2002 ident: 2020081004173003600_CIT0019 article-title: Sexual activity as a risk factor for hepatitis C publication-title: Hepatology contributor: fullname: Terrault – volume: 20 start-page: 2207 year: 2006 ident: 2020081004173003600_CIT0012 article-title: Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia publication-title: AIDS doi: 10.1097/QAD.0b013e328010c7d0 contributor: fullname: Long – volume-title: Gap report year: 2014 ident: 2020081004173003600_CIT0001 contributor: fullname: UNAIDS |
SSID | ssj0001105079 |
Score | 2.1996791 |
Snippet | We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs... Abstract Background We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people... BACKGROUNDWe evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | ofy040 |
SubjectTerms | Major |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3batwwEBVpAqUvpUlv2zRhCnlV64tsSYFQllzYDWwJpZvmzUi2nCwtdrv2Qven-o0ZXTZk08YYv8ieBx9JczQanSHkQMhcKPSDFFc6NWUm41QxyWkVS25YlefGyRdPvuSjKTu_yq42yKoYZ_iB3X-Xdrae1HT-8-Of38vPOOCPghjSJ0ShwscS--MTspWwlNmuPgk83wVbkEVETncPCYSgQmY8nNV78L3VBpaZtGW51h3VP-zzYRLlPa909oI8D3QShh7_bbJhmh3ydBI2zF-Sv-N7OY1wocofOH900Lfw1Wq2GkD-B2N3UhLaGkbjS1BNBaPjSxiHNK2mg6GtSAQXLtkcvt-02GbDN3AyX1x3MGvgVDm9BfCxfWcihI1h2M3UIQzBFl2zR999Y9v11KeShNkWbELj8hWZnp1-Ox7RUKKBlujqexqXidQqzTWPMpNwnbE6qpNcK2PSjJUqxSvWhnMlkCiIxKRVpSJpmI4UGqjT12SzaRvzloCScYIrZp3WUrEyTrRmeV1WthpKLZAIDsjBCo_il1fiKPwOelpYBAuP4IB8WGFV4Eix2x-qMe2iK5DqSBEJydHUG4_dnaEV6APC11C9e8GqcK-3NLMbp8adCWQ4EX_3qM1d8swHou39nmz284XZQybT633XS28BxnDzXA priority: 102 providerName: Scholars Portal |
Title | Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29594179 https://search.proquest.com/docview/2019808975 https://pubmed.ncbi.nlm.nih.gov/PMC5861407 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9swDBXaHoZdhn0v61ZwQK9ubEu2pN6CrEUyIFswtF1uhmTLbbBVLmrn0D-13zhKsotku80HXWQTAh4tUtQjScixkLlQaAcjPOnUETMZjxSTPKoSyQ2r8tz48sWLr_nskn1ZZas9kg25MJ60X-r1if11e2LXN55beXdbjgee2Hi5mGYCjUrMx_tkn1O6dUT3gRX0GGIu-1w8PLCPEaUKhwfUV1f7V2bStd3aNUT_eJd_kyS3rM75c_KsdxdhEpb1guwZ-5I8WfQX4q_I7_kWZxGWqvyJ-0MLXQPfXU1WA-jfwdxnQkJTw2x-BcpWMJtewbynYdkWJq7jECw9mRx-3DQ458Iz8Pl-c93C2sKZ8vUUIMTuvYg-LAyTdq1OYQKuqZpLbQ-TTdtFgSrS76bgCIsPr8nl-dnFdBb1LRiiEk15FyVlKrWiueZxZlKuM1bHdZprZQzNWKkoPok2nCuBjoBIDa0qFUvDdKxQQE3fkAPbWPOOgJJJiidiTWupWJmkWrO8LivX7aQW6OiNyPGAR3EXKm0U4YacFg7BIiA4Ip8GrAr8E9z1hrKm2bQFujJSxEJyFPU2YPcoaAB9RPgOqo8vuCrbuzOofL7adq9s7__7y0PyFJcmAnHtAzno7jfmI3oynT7yEQAcF0wceS3G8eLb6g928Ppp |
link.rule.ids | 230,315,733,786,790,870,891,2236,24346,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBa6Dth22fuRPTmgVyd-y9otyFrYW1MEQ5v1ZkiyvAZd5aJ2Dt2P2m8cJdlF0p02H3yRTdgQJX4UP5KE7GUszTjaQQ89ndqLVUI9HjPqVQGjKq7SVNnyxfOjND-Jv5wmpzskGXJhLGlfitVY_7wY69WZ5VZeXsjJwBObLOazJEOj4tPJHXIX12tIN5x0e7SCmMGnrM_GQ5d9gvNU4e0aNdZU_2UJM423tk3RX_jyNk1yw-4cPCLL4Ysd3eR8vO7EWP66Vczxn3_pMXnYI1GYuuEnZEfpp-TevI-1PyO_iw06JCy4PMetp4WugW-m3KsChI5Q2CRLaGrIiyVwXUE-W0LRM7x0C1PTzAgWlqcO388aHDMnP_D5av2jhZWGfW5LNYALC1gR_YkzTNsV_wRTMP3aTNa8G2zaznMslH6jBsOFvH5OTg72j2e513d38CSihM4LZMgEj1JB_USFVCRx7ddhKrhSURJLHuEVCEUpzxBjZKGKqor7TMXC5yigjl6QXd1o9YoAZ0GIzraIasZjGYRCxGktK9NIpc4QQ47I3jDR5aUr4lG64HtUGtUonWqMyMdBCUpcZCZywrVq1m2JKIllfsYoinrplOJG0KBNI0K31OXmAVPAe3sElcAW8u4n_fV_v_mB3M-P54flYXH09Q15gJ-ZOX7cW7LbXa3VOwRMnXhvl8cfAScZhA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXWl5lSwuD1Gs27zjmttp2tQG2WiFaKi6R7Th0VZqsmuyh_Ch-Y8d2Uu2WW3PIxc7IkceebzyfZwg5SlmScrSDDno6pROpmDo8YtQpfEZVVCSJMumLZ6fJ9Cz6chFfrJX6MqR9KRbD6s_1sFpcGm7l8lq6PU_Mnc_GcYpGxaPusijdp-QZrtmArTnq5ngFcYNHWXcjD912F-eqwNctaq3OAMxipotvbZqj_zDmQ6rkmu2Z7JBf_agt5eRquGrFUP59kNDxUb-1S150iBRGtstL8kRVr8j2rIu5vyb_sjVaJMy5vMItqIG2hu867asChJCQmcuWUJcwzc6BVwVMx-eQdUyvqoGRLmoEc8NXh5-XNbbpEyA4vln9bmBRwQk3KRvAhgeMiO7kGUbNgn-GEei6bfr2vG2sm9axbJRuwwbNibx9Q84mJz_GU6er8uBIRAut48uACR4mgnqxCqiIo9Irg0RwpcI4kjzExxeKUp4i1kgDFRYF95iKhMdRQBm-JVtVXal3BDjzA3S6RVgyHkk_ECJKSlnogiplilhyQI76yc6XNplHboPwYa7VI7fqMSCfekXIcbHpCAqvVL1qckRLLPVSRlHUnlWMe0G9Rg0I3VCZ-w46kfdmCyqCSejdTfz-o7_8SLbnx5P8W3b69T15jqNMLU3ugGy1Nyt1iLipFR_MCrkDs8YcBA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intervention+Packages+to+Reduce+the+Impact+of+HIV+and+HCV+Infections+Among+People+Who+Inject+Drugs+in+Eastern+Europe+and+Central+Asia%3A+A+Modeling+and+Cost-effectiveness+Study&rft.jtitle=Open+forum+infectious+diseases&rft.au=Mabileau%2C+Guillaume&rft.au=Scutelniciuc%2C+Otilia&rft.au=Tsereteli%2C+Maia&rft.au=Konorazov%2C+Ivan&rft.date=2018-03-01&rft.issn=2328-8957&rft.eissn=2328-8957&rft.volume=5&rft.issue=3&rft.spage=ofy040&rft_id=info:doi/10.1093%2Fofid%2Fofy040&rft_id=info%3Apmid%2F29594179&rft.externalDocID=29594179 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |